secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspire Biopharma Holdings, Inc. (ASBP)
CIK:        0001847345
Form:       8-K
Filed at:   2024-09-06T23:59:59+00:00
Accession:  0001493152-24-035298
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PowerUp Acquisition Corp. amends Aspire Biopharma merger; consideration set at $350M
--------------------------------------------------------------------------------

- Merger consideration adjusted to $350M less cash shortfall and debt, reflecting anticipated ownership percentages.
- Equity incentive plan pool set at greater of 10% of post-closing shares or 5M shares, with annual evergreen provision.
- Disclosure schedule delivery date extended to September 18, 2024, with 7-day review and cure period.
- Amendment signed September 5, 2024, provides additional time for due diligence and disclosure schedules.
- Deal remains subject to shareholder approvals and Nasdaq listing standards.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847345/000149315224035298/0001493152-24-035298-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847345/000149315224035298/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-035298

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer